Chief Financial Officer · SUTRO BIOPHARMA, INC. (STRO)

Gregory Chow

FY2025 is the first fiscal year CompBrief holds for Gregory Chow as a named executive officer of SUTRO BIOPHARMA; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$854,522

Compensation figures as of the proxy filed April 22, 2026 (DEF 14A).

Gregory Chow compensation by year

SUTRO BIOPHARMA Summary Compensation Table · the one fiscal year held
In US dollars, as SUTRO BIOPHARMA reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$277,083
Bonus$25,000
Stock awards$88,000
Option awards$245,938
Non-equity incentive$218,500
Pension and deferred compensation$0
All other$0
Total$854,522

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SUTRO BIOPHARMA, INC. DEF 14A filed April 22, 2026, accession 0001193125-26-170354, and prior-year filings. Open the filing on EDGAR.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU10,000$115,700—
Option8,200—$10.38
Option27,500—$8.80

Per the Outstanding Equity Awards at Fiscal Year-End table in SUTRO BIOPHARMA, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

SUTRO BIOPHARMA’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
William NewellFormer Chief Executive Officer$1,671,311
Jane ChungChief Executive Officer$1,575,930
Hans-Peter GerberChief Scientific Officer$942,902
Gregory Chow · this pageChief Financial Officer$854,522

The full SUTRO BIOPHARMA compensation record

free company brief

This page is one person within SUTRO BIOPHARMA's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order SUTRO BIOPHARMA's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SUTRO BIOPHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy